Vertex Pharmaceuticals (VRTX) trades at 22.9x forward P/E with 0.30 beta despite a flat two-year performance. Regeneron (REGN ...

The biotech group has struggled as a whole in 2025, but analysts say the innovation that has always supported the biotech ...

Biotech stocks are attracting investors as M&A activity, valuations and upcoming catalysts help drive sector momentum.

What are the most attractive biotech stocks right now for investors? Seeking Alpha analysts offer their picks. Read more here.

The latest trigger for Shanghai Henlius Biotech (SEHK:2696) is China’s approval of HANBEIYOU, its pertuzumab biosimilar for HER2-positive breast cancer, which rounds out authorizations in China, the ...

Expense ratios, yield, and sector breadth set these healthcare ETFs apart—see how their risk profiles and portfolio strategies compare.

The biotech sector has always held a special appeal for risk-tolerant investors. While these companies face high overhead in the form of towering R&D costs and long lead times for bringing new ...

As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd.

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics ...